Algert Global’s Pacira BioSciences PCRX Stock Holding History

Algert Global’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,625	Closed	-$502K	–	1296
2024 Q4	$502K	Sell	26,625 -32,223	-55%	-$566K	0.01%	907
2024 Q3	$886K	Buy	+58,848	New	+$1.01M	0.02%	774
2023 Q2	–	Sell	-45,103	Closed	-$1.84M	–	1209
2023 Q1	$1.84M	Buy	+45,103	New	+$1.79M	0.09%	379

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Algert Global's PCRX Position: Q1 2025 in Review

Algert Global sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 26,625 shares — an estimated $502K sold.

Algert Global first reported a position in PCRX in Q1 2023 and held it in 3 quarters. The position peaked at $1.84M in Q1 2023. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

Algert Global reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
Algert Global sold 26,625 Pacira BioSciences shares in Q1 2025, an estimated $502K.
Algert Global first reported a position in Pacira BioSciences in Q1 2023 and held it in 3 quarters.
Algert Global's Pacira BioSciences position peaked at $1.84M in Q1 2023.
235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.